^
    Back
    Association details:
    Biomarker:CDKN2A mutation
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Ibrance (palbociclib) (CDK4/6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AUA 2020
    Title:

    PD64-01: The status of the tumor suppressors VHL and CDKN2A impacts clear cell renal cell carcinoma sensitivity to CDK 4/6 inhibitors

    Published date:
    05/15/2020
    Excerpt:
    The FDA-approved CDK4/6 inhibitor palbociclib showed an effective response in ccRCC with wild-type VHL and mutated CDKN2A